Celltrion’s liver drug 'Godex' is experiencing a slump in the prescription market. At one point, its quarterly prescription sales exceeded KRW 20 billion but have been on a downward trend for the past 2 years. The company has been able to pass the health authorities' reimbursement reevaluations, but the drug price cut that followed left a performance gap.

According to the market research institution UBIST on Thursday, outpatient prescriptions for Godex amounted to KRW 17.8 billion in Q1, down 1.3% year-on-year. Compared to the KRW 20.6 billion in Q1 2022, this is a 13.5% decrease in 2 years. Godex's prescription sales in Q1 were the lowest in the last 4 years, after reaching KRW 17.3 billion in Q2 2020.